Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05847413 · ClinicalTrials.gov registry record · Early Phase 1
Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D
A Early Phase 1 study, sponsored by Benaroya Research Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT05847413 is a Early Phase 1 study that has completed, run by Benaroya Research Institute. The registered enrollment target is 10 participants.
The verdict
NCT05847413, a Early Phase 1 study, has completed, sponsored by Benaroya Research Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether verapamil can transiently improve beta cell function in those who do or do not secrete proinsulin and little/no C-peptide.
Interventions
- DRUG Verapamil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-05-30 |
| Est. Completion | 2021-12-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05847413
The ClinicalTrials.gov registry entry for NCT05847413 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Benaroya Research Institute, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Verapamil is the first listed.
NCT05847413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05847413 about?
NCT05847413 is a clinical study titled "Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D". The purpose of this study is to determine whether verapamil can transiently improve beta cell function in those who do or do not secrete proinsulin and little/no C-peptide.
What is the current status of trial NCT05847413?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2020-05-30. Estimated completion is 2021-12-10.
What interventions are being tested in trial NCT05847413?
The interventions under investigation include: Verapamil (DRUG).
Who is sponsoring clinical trial NCT05847413?
This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.